Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients
Randomized, phase III, predictive pharmacogenomic, open, prospective, international,
multicenter study in patients with non-small-cell lung carcinoma (NSCLC) after complete
resection and with N1 or N2 involvement
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate overall survival
5 years
No
Bartomeu Massutà Sureda, MD
Study Chair
HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE
Spain: Spanish Agency of Medicines
GECP-SCAT
NCT00478699
June 2007
December 2012
Name | Location |
---|